These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 3926308)

  • 1. Relevance of the pharmacology of oral tegafur to its use as a 5-FU pro-drug.
    Byfield JE; Hornbeck CL; Frankel SS; Sharp TR; Griffiths JC
    Cancer Treat Rep; 1985 Jun; 69(6):645-52. PubMed ID: 3926308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum concentrations of 5-FU, ftorafur, and a major serum metabolite following ftorafur chemotherapy.
    Hornbeck CL; Griffiths JC; Floyd RA; Ginther NC; Byfield JE; Sharp TR
    Cancer Treat Rep; 1981; 65(1-2):69-72. PubMed ID: 6784923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
    Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
    Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil.
    Muggia FM; Wu X; Spicer D; Groshen S; Jeffers S; Leichman CG; Leichman L; Chan KK
    Clin Cancer Res; 1996 Sep; 2(9):1461-7. PubMed ID: 9816321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous intravenous administration of 1-(2-tetrahydrofuryl)-5-fluorouracil [FT] by intravenous hyperalimentation (IVH)--stability of FT in IVH solution and tumor levels of 5-fluorouracil (5-FU).
    Moriya Y; Koyama Y; Hojo K; Tsunematsu R
    Jpn J Clin Oncol; 1983 Mar; 13(1):31-5. PubMed ID: 6403740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Serum concentration of 5-FU and tegafur (FT-207) after administration of tegafur (FT-207) suppository with the colostomy].
    Kimoto M; Nagano H; Gunge N; Murei T; Iwamoto S; Seo Y; Yamamoto Y; Sano K
    Gan To Kagaku Ryoho; 1987 Oct; 14(10):2853-8. PubMed ID: 3116942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer.
    Nogué M; Salud A; Batiste-Alentorn E; Saigí E; Losa F; Cirera L; Méndez M; Campos JM; Galan A; Escudero P; Arcusa A; Manzano H; de Mendizábal EV; de Olaguer JP; Boleda M; Guasch I; Vicente P
    Eur J Cancer; 2005 Oct; 41(15):2241-9. PubMed ID: 16214045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacokinetics and a phase I study of tegafur-uracil enterogranules in cancer patients].
    Kamiya O; Hoshino A; Ohara K; Nagata K; Kojima T; Sugihara T; Yamada M; Suzuki M; Kimura K; Fujii S
    Gan To Kagaku Ryoho; 1983 Dec; 10(12):2565-72. PubMed ID: 6418079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacokinetics of FT-207 rectum suppository in squamous cell carcinoma of the uterine cervix. (II) Pharmacokinetics in continuous administration at a daily dose of 1 gram].
    Okazaki H; Hasegawa T; Endoh S; Hayashi Y; Chin N; Rin K; Nakagiri Y; Ishii Y; Fukui H; Kohno I
    Gan To Kagaku Ryoho; 1984 Apr; 11(4):848-52. PubMed ID: 6426396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of continuous venous infusion of 5-FU and FT-207 under total parenteral nutrition].
    Tane S; Ogawa Y; Kido Y; Naruko M; Niwa H; Abe Y; Kobayashi M; Mori T
    Gan To Kagaku Ryoho; 1986 Oct; 13(10):2947-53. PubMed ID: 3094454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [FT-207 and 5-FU concentrations in brain tumor tissues, plasma and CSF after administration of FT-207 suppository].
    Matsuura H; Nakazawa S
    Gan To Kagaku Ryoho; 1984 Apr; 11(4):912-6. PubMed ID: 6426399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Combination therapy of continuous venous infusion (CVI) of 5-FU and low dose consecutive cisplatin (CDDP), and the new oral anti-cancer drug S-1 for advanced gastro-intestinal cancer].
    Shirasaka T; Aiba K; Araki H; Suzuki M; Terashima M; Mikami Y
    Gan To Kagaku Ryoho; 1999 Mar; 26(4):456-66. PubMed ID: 10097742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of intravenous administration of FT-207 for gastric cancer].
    Otani Y; Yamanaka T; Kikuchi H; Namatame K; Yoshida K; Kataba Y; Maruyama Y; Watanabe H
    Gan To Kagaku Ryoho; 1985 Apr; 12(4):857-60. PubMed ID: 3920970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacologic study of oral ftorafur and X ray therapy in advanced gastrointestinal cancer.
    Byfield JE; Sharp TR; Hornbeck CL; Frankel SS; Floyd RA; Griffiths JC
    Int J Radiat Oncol Biol Phys; 1985 Mar; 11(3):597-602. PubMed ID: 3918971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxylated metabolies of R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (Ftorafur) in rats and rabbits.
    Wu AT; Au JL; Sadée W
    Cancer Res; 1978 Jan; 38(1):210-4. PubMed ID: 338145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.
    Hirata K; Horikoshi N; Aiba K; Okazaki M; Denno R; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Shirasaka T
    Clin Cancer Res; 1999 Aug; 5(8):2000-5. PubMed ID: 10473078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
    Shirasaka T; Shimamoto Y; Kato T; Fukushima M
    Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical study of serum and tissue concentrations of FT-207 and 5-FU in patients with cancer of the large intestine following preoperative application of FT-207 suppositories].
    Okuda M; Teramoto T; Yoshida H; Sato K; Ushijima Y; Uematsu Y
    Gan To Kagaku Ryoho; 1982 Sep; 9(9):1580-8. PubMed ID: 6820920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU from bench to clinic.
    Shirasaka T
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():193-205. PubMed ID: 10895155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU].
    Shirasaka T; Yamamitsu S; Tsuji A; Terashima M; Hirata K
    Gan To Kagaku Ryoho; 2000 Jun; 27(6):832-45. PubMed ID: 10897209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.